These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 30297385

  • 21. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH, Robinson BG, Learoyd DL.
    Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
    [Abstract] [Full Text] [Related]

  • 22. YAP confers resistance to vandetanib in medullary thyroid cancer.
    Wang H, Tang J, Su Z.
    Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
    Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF.
    Endocr Relat Cancer; 2019 Feb 01; 26(2):241-250. PubMed ID: 30557850
    [Abstract] [Full Text] [Related]

  • 28. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
    Broutin S, Commo F, De Koning L, Marty-Prouvost B, Lacroix L, Talbot M, Caillou B, Dubois T, Ryan AJ, Dupuy C, Schlumberger M, Bidart JM.
    Thyroid; 2014 Jan 01; 24(1):43-51. PubMed ID: 24256343
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ, Magalhães PKR.
    Arch Endocrinol Metab; 2017 Jan 01; 61(4):398-402. PubMed ID: 28658345
    [Abstract] [Full Text] [Related]

  • 31. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A, Saji M, Yu L, Zhang X, Bumrah C, Yilmaz AS, Knippler CM, Miles W, Giordano TJ, Cote GJ, Ringel MD.
    JCI Insight; 2018 Aug 23; 3(16):. PubMed ID: 30135308
    [Abstract] [Full Text] [Related]

  • 32. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
    Wang SX, Zhang XW, Wang XX, An CM, Zhang YB, Liu W, Zhao YF, He XH, Li ZJ, Niu LJ, Tang PZ.
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun 07; 54(6):439-444. PubMed ID: 31262109
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.
    Thyroid; 2017 Sep 07; 27(9):1142-1148. PubMed ID: 28635560
    [Abstract] [Full Text] [Related]

  • 35. Vandetanib: first global approval.
    Commander H, Whiteside G, Perry C.
    Drugs; 2011 Jul 09; 71(10):1355-65. PubMed ID: 21770481
    [Abstract] [Full Text] [Related]

  • 36. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
    Narayanan VK, Ronghe M, MacGregor FB, Bradshaw N, Davidson R, Welbury R, Reed N, Shaikh MG.
    J Pediatr Hematol Oncol; 2016 Mar 09; 38(2):155-7. PubMed ID: 26479990
    [Abstract] [Full Text] [Related]

  • 37. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
    Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V.
    ESMO Open; 2021 Apr 09; 6(2):100079. PubMed ID: 33721621
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, Martin PD, Jiang Y, Liao H, Guan Z.
    Clin Ther; 2011 Mar 09; 33(3):315-27. PubMed ID: 21600385
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
    Almeida MQ, Hoff AO.
    Curr Opin Oncol; 2012 May 09; 24(3):229-34. PubMed ID: 22343387
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.